Tedizolid CAS number is 856866-72-3, an oroxazolidinone antibiotic, trade name is Sivextro, which is used to treat adults caused by Gram-positive bacteria such as Staphylococcus aureus, various Streptococci and Enterococci Acute bacterial skin and skin tissue infections. The medicinal ingredient of Sivextro is the sodium salt of Tedizolid Phosphate. It is available in injections and tablets. It was approved by the US FDA on June 20, 2014.
Tedizolid CAS number 856866-72-3 is a new antibacterial prodrug of oxazolidone. It is available in two dosage forms, 200 mg lyophilized powder for intravenous injection and 200 mg tablets. Among them, the lyophilized powder injection is formulated with tedizolid disodium salt, and the tablets are made by direct compression of tedizolium free acid plus excipients.
Tedizolid is sensitive to humidity and heat. The inventors have found through experiments that wet-granulation of Tedizolid phosphate tablets requires high temperature drying. The granules produced have poor fluidity and compressibility. In order to overcome the defect of instability of the drug substance to heat and humidity, it was directly prepared by directly pressing the powder with a filler, a disintegrant, a glidant, a lubricant, etc., which can not only overcome the lack of properties of the drug substance, It can also reduce the types and amounts of excipients, use the simplest process to achieve higher bioavailability, good patient compliance, stable preparation, simple operation, and good reproducibility.
Tedizolid CAS number is 856866-72-3, which is a second-generation oxazolidinone antibiotic, is an analog of linezolid, is a protein synthesis inhibitor, acts on the bacterial ribosome 50S subunit, and inhibits bacterial proteins Synthesis. Compared with linezolid, the effects are basically the same, but linezolid needs to be taken twice a day for 10 consecutive days, while tedizolid is only taken once a day for 6 consecutive days.
The safety and effectiveness of tedizolid CAS 856866-72-3 was evaluated in two clinical trials involving 1,315 adult patients with acute bacterial skin and skin tissue infections caused by various Streptococcus and Enterococcus faecalis. Subjects were randomly assigned to tedizolid or linezolid. The results show that its clinical effect is comparable to that of linezolid, with less adverse reactions in gastrointestinal tract and thrombocytopenia than linezolid, and the incidence of drug resistance is lower. Tests have shown that tedizolid is better tolerated than vancomycin.
On June 20, 2014, the U.S. FDA approved a new antibacterial drug, tedizolid, for the treatment of adult patients with skin infections. Tedizolid is approved for the treatment of acute bacterial skin and skin tissue infections caused by certain sensitive bacteria such as Staphylococcus aureus, various Streptococci and Enterococcus faecalis. Tedizolid is administered intravenously and orally.
Thera. Category: Anti-bacterial
Cas No.: 856866-72-3
Synonym:(R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one,Torezolid;
Molecular Formula:C17H15FN6O3
Molecular Weight: 370.3378032
Purity: ≥98.%
Packing: Export worthy packing
Material Safety Data Sheet: Available on request
Tedizolid CAS 856866-72-3
Tedizolid phosphate Cas number 856867-55-5
(5R)-3-(4-BROMO-3-FLUOROPHENYL)-5-HYDROXYMETHYLOXAZOLIDIN-2-ONE CAS number 444335-16-4
5-BROMO-2-(2-METHYL-2H-TETRAZOL-5-YL)-PYRIDINE Cas 380380-64-3
(5R)-3-(3-FLUORO-4-IODOPHENYL)-5-HYDROXYMETHYLOXAZOLIDIN-2-ONE CAS 487041-08-7.
(R)-3-(3-FLUOROPHENYL)-5-(HYDROXYMETHYL)OXAZOLIDIN-2-ONE CAS number149524 -42-5
2-(2-Methyl-2H-tetrazol-5-yl)pyridine-5-boronic acid pinacol ester CAS 1056039-83-8